# Phase 2/3 leukemia trials recruiting: 23 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 23 trials in phase 2/3 for leukemia that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 2/3 leukemia trials: 23 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-2-3/leukemia

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 23
- Recruiting or not yet: 23
- Read on: November 19, 2026

## Trials

The 23 newest of 23, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| June 3, 2026 | NCT07623187 | A Study to Assess How Well the Study Medicine IPN60340 Works in Combination With Azacitidine and Venetoclax, Compared to Placebo in... | Ipsen | Phase 2/3 | Not yet recruiting | Acute Myeloid Leukaemia (AML), Acute Myeloid Leukaemia | 540 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07623187) |
| May 20, 2026 | NCT07597941 | Lisaftoclax for Prevention of Differentiation Syndrom in Acute Promyelocytic Leukemia Patients | The Affiliated People's Hospital of Ningbo University | Phase 2/3 | Not yet recruiting | Acute Promyelocytic Leukemia (APL) | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07597941) |
| May 13, 2026 | NCT07583888 | VABu Conditioning in Elderly AML HSCT | The First Affiliated Hospital of Soochow University | Phase 2/3 | Recruiting | Allogeneic Hematopoietic Stem Cell Transplantation Recipient, Acute Myeloid Leukemia (AML) | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07583888) |
| May 12, 2026 | NCT07581002 | A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral... | AbbVie | Phase 2/3 | Recruiting | Acute Myeloid Leukemia | 660 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07581002) |
| February 23, 2026 | NCT07425808 | FLT3-ITD Targeted Therapy in Fit AML Patients | European Organisation for Research and Treatment of Cancer - EORTC | Phase 2/3 | Not yet recruiting | AML (Acute Myeloid Leukemia) | 230 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07425808) |
| January 26, 2026 | NCT07366801 | Co-infusion of Treg-enriched Donor Lymphocytes With CD3-depleted Hematopoietic Stem Cell Graft to Prevent Graft-versus Host Disease After... | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | Phase 2/3 | Recruiting | Acute Myeloid Leukemia, Relapsed, Acute Lymphoblastic Leukemia, High Risk, Acute Myeloid Leukemia, High Risk, Acute... | 64 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07366801) |
| December 4, 2025 | NCT07264010 | Sorafenib Combined With Venetoclax as Pre-emptive Therapy Strategy for MRD+ AML: a Prospective, Single-arm, Multicenter Clinical Study | Nanfang Hospital, Southern Medical University | Phase 2/3 | Not yet recruiting | Acute Myeloid Leukaemia (AML), Measurable Residual Disease (MRD) | 87 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07264010) |
| December 1, 2025 | NCT07255872 | A Study of BL-M11D1 in Combination With Cytarabine + Daunorubicin or Venetoclax + Azacitidine in Patients With Acute Myeloid Leukemia | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 2/3 | Recruiting | Acute Myeloid Leukemia | 216 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07255872) |
| October 1, 2025 | NCT07202091 | Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Immunoglobulin Stopping or Extension (Stop Ig) | Monash University | Phase 2/3 | Recruiting | Myeloma, Leukemia, Non Hodgkin&#39;s Lymphoma | 900 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07202091) |
| October 1, 2025 | NCT07202078 | Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Starting Immunoglobulin (Start Ig) | Monash University | Phase 2/3 | Recruiting | Myeloma, Non Hodgkin&#39;s Lymphoma, Leukemia | 900 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07202078) |
| October 1, 2025 | NCT07202065 | Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Dosing Immunoglobulin (Dose Ig) | Monash University | Phase 2/3 | Recruiting | Myeloma, Non Hodgkin&#39;s Lymphoma, Leukemia | 900 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07202065) |
| October 1, 2025 | NCT07202052 | Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial (RATIONAL-PT) | Monash University | Phase 2/3 | Recruiting | Myeloma, Non-Hodgkin's Lymphoma, Leukemia | 900 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07202052) |
| September 5, 2025 | NCT07157514 | Radioimmunotherapy Conditioning With 131I- Apamistamab for Allogeneic Transplant in Relapse/Refractory AML | Actinium Pharmaceuticals | Phase 2/3 | Not yet recruiting | Acute Leukemia, Myeloid Leukemia, Acute Myelogenous Leukemia, Acute Myeloid Leukemia, Acute Myeloid Leukemia, in... | 306 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07157514) |
| March 26, 2025 | NCT06895538 | Comparison of ATLG and ATG for Immune Reconstitution After Allo-HSCT for Hematologic Malignancy | Peking University First Hospital | Phase 2/3 | Recruiting | Leukemia, MDS, Lymphoma | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06895538) |
| January 23, 2025 | NCT06788756 | L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With... | Moleculin Biotech, Inc. | Phase 2/3 | Recruiting | Acute Myeloid Leukaemia (AML) | 312 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06788756) |
| January 1, 2025 | NCT06756152 | Preventing of GVHD with Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Ruxolitinib At Children and Young Adults with... | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | Phase 2/3 | Recruiting | Biphenotypic Acute Leukemia, Acute Lymphoblastic Leukemia, Myeloblastic Leukemia, Bilinear Leukemia, Malignant... | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06756152) |
| April 7, 2023 | NCT05805098 | Venetoclax Combined With Homoharringtonine and Cytarabine in Induction for AML | The First Affiliated Hospital of Soochow University | Phase 2/3 | Recruiting | Acute Myeloid Leukemia | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05805098) |
| January 10, 2023 | NCT05678621 | Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Immunoglobulin Stopping or Extension | Monash University | Phase 2/3 | Recruiting | Haematological Malignancy, Hypogammaglobulinemia | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05678621) |
| June 3, 2022 | NCT05404906 | AZA + Venetoclax as Maintenance Therapy in Younger Adults With AML in First Remission | The First Affiliated Hospital of Soochow University | Phase 2/3 | Recruiting | Acute Myeloid Leukemia (AML) in Remission | 124 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05404906) |
| January 13, 2021 | NCT04708054 | Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS | M.D. Anderson Cancer Center | Phase 2/3 | Recruiting | Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome | 324 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04708054) |
| February 5, 2020 | NCT04256317 | A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND... | Taiho Oncology, Inc. | Phase 2/3 | Recruiting | Myelodysplastic Syndromes, Acute Myeloid Leukemia, Myelodysplastic Syndrome/Neoplasm, Chronic Myelomonocytic Leukemia | 316 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04256317) |
| April 15, 2015 | NCT02416388 | Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus... | University Hospital, Angers | Phase 2/3 | Recruiting | Acute Myeloid Leukemia (AML) | 3,100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02416388) |
| May 6, 2014 | NCT02131753 | Therapy Optimisation for the Treatment of Hairy Cell Leukemia | University of Giessen | Phase 2/3 | Recruiting | Hairy Cell Leukemia | 210 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02131753) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Monash University | 5 |
| The First Affiliated Hospital of Soochow University | 3 |
| Federal Research Institute of Pediatric Hematology, Oncology and Immunology | 2 |
| Moleculin Biotech, Inc. | 1 |
| The Affiliated People's Hospital of Ningbo University | 1 |
| [AbbVie](https://specstream.ai/data/clinical-trials/company/abbvie) | 1 |
| University Hospital, Angers | 1 |
| University of Giessen | 1 |
| [Taiho Oncology, Inc.](https://specstream.ai/data/clinical-trials/company/taiho-oncology-inc) | 1 |
| Actinium Pharmaceuticals | 1 |
| M.D. Anderson Cancer Center | 1 |
| Peking University First Hospital | 1 |
| European Organisation for Research and Treatment of Cancer - EORTC | 1 |
| Nanfang Hospital, Southern Medical University | 1 |
| [Sichuan Baili Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/sichuan-baili-pharmaceutical-co-ltd) | 1 |
| [Ipsen](https://specstream.ai/data/clinical-trials/company/ipsen) | 1 |

## By country

| Country | Trials |
| --- | --- |
| China | 5 |
| Australia | 5 |
| United States | 4 |
| Spain | 3 |
| France | 3 |
| Czechia | 2 |
| Italy | 2 |
| Poland | 2 |
| Russia | 2 |
| Germany | 2 |
| Georgia | 1 |
| Lithuania | 1 |
| Romania | 1 |
| Ukraine | 1 |
| Austria | 1 |
| Israel | 1 |
| South Korea | 1 |
| Taiwan | 1 |
| Canada | 1 |
| Hungary | 1 |
| United Kingdom | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Persian restaurants in the United States](https://specstream.ai/data/businesses/persian-restaurants/united-states)
- [Forestry services in the United States](https://specstream.ai/data/businesses/forestry-services/united-states)
- [B2B quarry companies in the United States](https://specstream.ai/data/businesses/b2b-quarry-companies/united-states)
- [Restaurant equipment suppliers in the United States](https://specstream.ai/data/businesses/restaurant-equipment-suppliers/united-states)
- [Hydro jetting companies in the United States](https://specstream.ai/data/businesses/hydro-jetting-companies/united-states)
- [Cardiothoracic surgery practices in the United States](https://specstream.ai/data/businesses/cardiothoracic-surgery-practices/united-states)
